|
Rabeximod
|
DB05772 |
[Rabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.] |
|
LLL-3348
|
DB05771 |
[The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.] |
|
2-Chlorophenol
|
DB03110 |
|
|
2-Fluoroadenosine
|
DB04441 |
|
|
2,4-Difluorobenzyl Alcohol 2,4-Difluoro-1-(Hydroxymethyl)Benzene
|
DB04448 |
|
|
2-carboxypropyl-coenzyme A
|
DB03117 |
|
|
(2Z)-1-(5-Chloro-1H-indol-3-yl)-3-hydroxy-3-(1H-tetrazol-5-yl)-2-propen-1-one
|
DB03118 |
|
|
5-(3,3-Dihydroxypropeny)-3-Methoxy-Benzene-1,2-Diol
|
DB04449 |
|
|
Oglufanide
|
DB05779 |
[Oglufanide is a synthetic dipeptide immunomodulator in development for the treatment of chronic hepatitis C viral infection. Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by Implicit Bioscience in 2005. Oglufanide works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection.] |
|
Col-118
|
DB05778 |
[COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders. It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. Col-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist.] |
|
Benzo[B]Thiophene-2-Carboxamidine
|
DB04446 |
|
|
5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
|
DB03115 |
|
|
5-(1-Carboxy-1-Phosphonooxy-Ethoxyl)-Shikimate-3-Phosphate
|
DB03116 |
|
|
1,4-Dithiothreitol
|
DB04447 |
[A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]] |
|
Thrombomodulin Alfa
|
DB05777 |
[Thrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism. [A18701]] |
|
IC41
|
DB05776 |
[IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C. The vaccine consists of five synthetic peptides (IPEP83, 84, 87, 89,1426) harboring HCV CD4 and CD8 T-cell epitopes and the synthetic adjuvant poly-L-arginine. ] |
|
Tetrafluoroaluminate Ion
|
DB04444 |
|
|
3-Fluoro-2-(Phosphonooxy)Propanoic Acid
|
DB03113 |
|
|
PAS219
|
DB03114 |
|
|
Mercuric iodide
|
DB04445 |
|
